Aberrant DNA methylation and prostate cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Prostate cancer (PCa) is a leading cause of cancer-related death in men.
• Somatic epigenetic alterations, unlike variable genetic changes, are early and consistent in PCa.
• Epigenetics involves DNA methylation, histone modifications, and RNA interference, regulating gene expression and malignancy-associated phenotypes.

Purpose of the Study:

• To explore the role of epigenetic alterations, specifically DNA methylation, in prostate cancer.
• To evaluate the potential of epigenetic markers for PCa diagnosis, prognosis, and therapy.

Main Methods:

• Review of epigenetic phenomena including DNA methylation, histone modifications, RNA interference, and genomic imprinting.
• Identification of hypermethylated genes in PCa and benign prostate hyperplasia.
• Discussion of genome-wide screening methodologies for epigenetic signature identification.

Main Results:

• Aberrant DNA methylation is associated with PCa progression and benign prostate hyperplasia.
• Epigenetic alterations can influence malignancy-associated phenotypes like growth, migration, invasion, and angiogenesis.
• DNA methylation markers are sensitive, detectable in various body fluids, and suitable for high-throughput studies.

Conclusions:

• Aberrant DNA methylation presents significant potential as diagnostic and prognostic markers for PCa.
• Epigenetic alterations are reversible, offering possibilities for targeted PCa therapies.
• Environmental and dietary factors may influence global and gene-specific DNA methylation patterns.